AstraZeneca Clinical Trials

Naropin™ (ropivacaine) is currently indicated for surgical anaesthesia via the epidural and intrathecal (spinal) routes of administration, major nerve blocks and field block infiltration. It is also indicated for acute pain management via the epidural route and also field blocks, intra-articular injection and continuous peripheral nerve block.

Please consult the prescribing information for the country concerned for guidance on the approved use of Naropin™ (ropivacaine).

Study Number	Completed Clinical Trial Report Summaries
CF-ROP-0005	Femoral infusion of ropivacaine 2 mg/mL for the management of postoperative pain after major knee surgery. A comparison of three strategies: patient-controlled femoral analgesia (PCFA), continuous infusion, and PCFA + continuous infusion.
D0695L00002	A randomised, double-blind, multi-centre, parallel group study comparing efficacy and safety of 5 mg/ml ropivacaine and 5 mg/ml bupivacaine for spinal anaesthesia in patients undergoing unilateral lower limb surgery.
SP-ROA-0013	Efficacy and tolerability of 1, 2 and 3mg/kg ropivacaine administered as a single caudal block for pain management after inguinal surgery in children aged 4-12 years with a body weight of up to 25kg: a comparative, randomized and double-blind study.
SP-ROA-0021	A double-blind study comparing efficacy and tolerability of 7.5 mg/ml and 10 mg/ml ropivacaine for subarachnoid anaesthesia in patients undergoing total hip arthroplasty.
SP-ROA-0022	A double-blind placebo controlled study comparing efficacy and tolerability of intra-articular saline, 7.5 mg/ml or 10 mg/ml ropivacaine following arthroscopic knee surgery.
SP-ROA-0025	Intrathecal administration of ropivacaine 5 mg/ml and bupivacaine 5 mg/ml to patients undergoing total hip arthroplasty. A double-blind efficacy study.